BACKGROUND: Porcine reproductive and respiratory syndrome (PRRS) is one of the most serious diseases affecting the swine industry worldwide; however, there are no efficient control strategies against PRRS virus (PRRSV) at present. Therefore, development of new antiviral treatment strategies is urgently needed. As reported, lithium chloride (LiCl) can efficiently impair the replication of a variety of viruses, including infectious bronchitis coronavirus (IBV) and transmissible gastroenteritis coronavirus (TGEV). In this report, we explored whether LiCl had the potential to inhibit PRRSV infection. METHODS: MARC-145 cells were treated with LiCl at various stages of PRRSV life cycle. Virus titration assay was performed to determine the virus infectivity. The expression of viral mRNA and protein was measured by real-time PCR and indirect immunofluorescence assay, respectively. The transcript levels of cytokines were evaluated by real-time PCR. RESULTS: LiCl significantly suppressed the synthesis of viral RNA and protein; however, it did not block PRRSV binding and entry. Further studies confirmed that LiCl inhibited PRRSV replication at an early stage and TNF-α, an antiviral cytokine, was significantly increased after LiCl treatment. Thus, we suggested that LiCl inhibited PRRSV infection by up-regulating the level of antiviral cytokine TNF-α at an early infection stage. CONCLUSIONS: Our findings imply that the LiCl has the potential to be used as anti-PRRSV therapy.
BACKGROUND:Porcine reproductive and respiratory syndrome (PRRS) is one of the most serious diseases affecting the swine industry worldwide; however, there are no efficient control strategies against PRRS virus (PRRSV) at present. Therefore, development of new antiviral treatment strategies is urgently needed. As reported, lithium chloride (LiCl) can efficiently impair the replication of a variety of viruses, including infectious bronchitis coronavirus (IBV) and transmissible gastroenteritis coronavirus (TGEV). In this report, we explored whether LiCl had the potential to inhibit PRRSVinfection. METHODS: MARC-145 cells were treated with LiCl at various stages of PRRSV life cycle. Virus titration assay was performed to determine the virus infectivity. The expression of viral mRNA and protein was measured by real-time PCR and indirect immunofluorescence assay, respectively. The transcript levels of cytokines were evaluated by real-time PCR. RESULTS:LiCl significantly suppressed the synthesis of viral RNA and protein; however, it did not block PRRSV binding and entry. Further studies confirmed that LiCl inhibited PRRSV replication at an early stage and TNF-α, an antiviral cytokine, was significantly increased after LiCl treatment. Thus, we suggested that LiCl inhibited PRRSVinfection by up-regulating the level of antiviral cytokine TNF-α at an early infection stage. CONCLUSIONS: Our findings imply that the LiCl has the potential to be used as anti-PRRSV therapy.
Authors: Andrea Murru; Mirko Manchia; Tomas Hajek; René E Nielsen; Janusz K Rybakowski; Gabriele Sani; Thomas G Schulze; Leonardo Tondo; Michael Bauer Journal: Int J Bipolar Disord Date: 2020-05-20
Authors: Carlos Spuch; Marta López-García; Tania Rivera-Baltanás; J J Cabrera-Alvargonzález; Sudhir Gadh; Daniela Rodrigues-Amorim; Tania Álvarez-Estévez; Almudena Mora; Marta Iglesias-Martínez-Almeida; Luis Freiría-Martínez; Maite Pérez-Rodríguez; Alexandre Pérez-González; Ana López-Domínguez; María Rebeca Longueira-Suarez; Adrián Sousa-Domínguez; Alejandro Araújo-Ameijeiras; David Mosquera-Rodríguez; Manuel Crespo; Dolores Vila-Fernández; Benito Regueiro; Jose Manuel Olivares Journal: Front Pharmacol Date: 2022-04-14 Impact factor: 5.988
Authors: Carlos Spuch; Marta López-García; Tania Rivera-Baltanás; Daniela Rodrígues-Amorím; José M Olivares Journal: Front Pharmacol Date: 2020-08-27 Impact factor: 5.810